Gene Expression Atlas home | about the project | faq | feedback | blog | das | api | help
TRAF3
REST API REST API
Homo sapiens
TRAF3 is differentially expressed in 310 experiments: 127 organism parts: lung, bone marrow, ... (125 more);, 197 disease states: normal, breast carcinoma, ... (195 more);, 91 cell types 407 cell lines 44 compound treatments and 71 other conditions.
Synonyms LAP1, CAP-1, CRAF1, CD40bp
Orthologs Traf3 (Rattus norvegicus)   TRAF3 (Gallus gallus)   traf3 (Danio rerio)   ENSCING00000001576 (Ciona intestinalis)   ENSCING00000000789 (Ciona intestinalis)   ENSCING00000002932 (Ciona intestinalis)   Traf3 (Mus musculus)   TRAF3 (Bos taurus)   ENSCING00000014078 (Ciona intestinalis)   ENSCING00000000553 (Ciona intestinalis)   ENSCING00000000554 (Ciona intestinalis)   ENSCING00000017424 (Ciona intestinalis)   ENSCING00000015912 (Ciona intestinalis)   Traf-like (Drosophila melanogaster)   traf3 (Xenopus laevis)   TRAF3 (Canis familiaris)   (Compare orthologs)
Gene Ontology Term cytosol, ligase activity, protein binding, cytoplasm, innate immune response, metal ion binding, signal transducer activity, induction of apoptosis, protein kinase binding, ubiquitin-protein ligase activity, endosome, regulation of proteolysis, signal transduction, mitochondrion, zinc ion binding, regulation of apoptosis, tumor necrosis factor-mediated signaling pathway, internal side of plasma membrane, toll-like receptor signaling pathway, negative regulation of NF-kappaB transcription factor activity, regulation of cytokine production, regulation of defense response to virus, regulation of interferon-beta production, CD40 receptor complex, negative regulation of type I interferon production
InterPro Term MATH, Znf_RING, Znf_TRAF, TNF_rcpt--assoc_TRAF
UniProt Accession Q13114, A6NHG8
Search EB-eye ENSG00000131323
Show more properties
Experimental Factors
Organism part

studied in E-GEOD-15765, E-GEOD-803, E-GEOD-1577, E-GEOD-2549, E-GEOD-3526, ... (25 experiments)

3
1
Number of published studies where the gene is over/under expressed compared to the gene's overall mean expression level in the study.

anatomogram

Cell line

studied in E-GEOD-17482, E-GEOD-5258, E-GEOD-4525, E-GEOD-19639, E-GEOD-18005, ... (43 experiments)

Factor Value U/D Experiments
BT474
3
E-MTAB-37, E-MTAB-62, E-MEXP-440
primary culture
2
E-GEOD-1657, E-GEOD-2450
MDAMB175VII
2
E-MTAB-37, E-MTAB-62
A549
2
E-GEOD-6013, E-GEOD-3202
DU145
2
E-GEOD-17482, E-GEOD-20089
MDA-MB-231
2
E-TABM-420, E-MTAB-62
401 more value(s).


Cell type

studied in E-GEOD-20193, E-GEOD-22373, E-GEOD-21668, E-GEOD-3920, E-GEOD-360, ... (47 experiments)

Factor Value U/D Experiments
partially reprogrammed human induced pluripotent stem cell
2
E-GEOD-18265, E-GEOD-18147
721 B lymphoblast
2
E-AFMX-5, E-TABM-145
macrophage
2
E-GEOD-22373, E-GEOD-360
iPS cells from episomal vectors (Defined Factor)
1
E-GEOD-20033
promyelocyte
1
E-GEOD-12662
intrathymic T progenitor cell
1
E-GEOD-1460
85 more value(s).


Disease state

studied in E-GEOD-3307, E-GEOD-15960, E-GEOD-2466, E-GEOD-1577, E-TABM-15, ... (55 experiments)

Factor Value U/D Experiments
chronic lymphocytic leukemia
3
E-MTAB-37, E-GEOD-2466, E-GEOD-6691
glioblastoma
3
E-GEOD-4290, E-MTAB-62, E-GEOD-4412
colon carcinoma
2
E-MTAB-62, E-GEOD-3726
multiple myeloma
2
E-MTAB-62, E-GEOD-6691
myxoid liposarcoma
2
E-GEOD-6481, E-MTAB-62
lung adenocarcinoma
1
2
E-MTAB-62, E-GEOD-2514, E-MTAB-37
191 more value(s).


Compound treatment

studied in E-GEOD-5258, E-GEOD-1417, E-TABM-782, E-GEOD-3720, E-GEOD-5824, ... (31 experiments)

Factor Value U/D Experiments
lipopolysaccharide
3
E-TABM-868, E-MEXP-1958, E-GEOD-3720
Cxcl12
1
1
E-GEOD-7307
mannitol
1
E-GEOD-6400
4,5-dianilinophthalimide
2
1
E-GEOD-5258
NaOH
1
E-MEXP-2590
anti-CD3 antibody (clone:OKT3)
1
E-MEXP-1601
38 more value(s).


Agent

studied in E-GEOD-19519

Factor Value U/D Experiments
tunicamycin
1
E-GEOD-19519
thapsigargin
1
E-GEOD-19519


Biosource provider
studied in E-MTAB-37

BioSourceProvider
studied in E-GEOD-19519, E-GEOD-19480

Blood/non-blood meta-groups
studied in E-MTAB-62

Bmngrd
studied in E-GEOD-20194, E-GEOD-16716

Cancer site
studied in E-GEOD-4271

Cell treatment
studied in E-MEXP-1192

Cellular component
studied in E-GEOD-1400

Clinical history
studied in E-GEOD-22097, E-GEOD-19420, E-GEOD-19743, E-GEOD-7967, E-GEOD-21374, ... (10 experiments)

Clinical info
studied in E-GEOD-19743, E-MTAB-37, E-GEOD-6710, E-MEXP-1251, E-GEOD-21374, ... (9 experiments)

Clinical treatment
studied in E-GEOD-6532

coriell cell line repository identifier
studied in E-GEOD-19519

development stage
studied in E-GEOD-22601

Developmental stage
studied in E-GEOD-20033, E-GEOD-3140, E-MEXP-2359, E-GEOD-2666, E-GEOD-4667, ... (7 experiments)

Disease stage
studied in E-GEOD-7463

Disease staging
studied in E-GEOD-89, E-GEOD-19743, E-GEOD-3325, E-TABM-147, E-GEOD-21138, ... (7 experiments)

Environmental stress
studied in E-GEOD-1643, E-GEOD-3720

Estrogen receptor status
studied in E-GEOD-6532, E-GEOD-20194, E-GEOD-16716

Ethnic group
studied in E-GEOD-20194, E-GEOD-16716

Ethnicity
studied in E-GEOD-16363

family id
studied in E-GEOD-19519

Family relationship
studied in E-MEXP-1425

Genetic modification
studied in E-GEOD-8023, E-MTAB-73, E-MEXP-1482, E-GEOD-7578, E-GEOD-17385, ... (7 experiments)

Genotype
studied in E-TABM-763, E-MEXP-1437, E-GEOD-2466, E-GEOD-17476, E-MEXP-421, ... (11 experiments)

Gestation age
studied in E-GEOD-14334

369 groups
studied in E-MTAB-62

4 groups from blood to incompletely diff
studied in E-MTAB-62

96 groups
studied in E-MTAB-62

Growth condition
studied in E-GEOD-13073, E-GEOD-6432, E-GEOD-5681, E-TABM-127, E-MEXP-1446, ... (8 experiments)

Her2 fish
studied in E-GEOD-20194, E-GEOD-16716

Her2 ihc
studied in E-GEOD-20194, E-GEOD-16716

Histology
studied in E-TABM-234, E-GEOD-21653, E-TABM-276

Individual
studied in E-TABM-325, E-MTAB-197, E-GEOD-2466, E-MEXP-2069, E-MEXP-1648, ... (33 experiments)

Infection
studied in E-MEXP-1274, E-GEOD-2405, E-GEOD-12108, E-GEOD-12254, E-GEOD-6802 ... (5 experiments)

Injury
studied in E-GEOD-19743

Karyotype
studied in E-GEOD-7214, E-GEOD-12662

Ki67 ihc
studied in E-GEOD-21653

Labeling
studied in E-LGCL-5

Lymph node status
studied in E-GEOD-6532

Material type
studied in E-MEXP-455, E-GEOD-9171

15 meta groups
studied in E-MTAB-62

4 meta groups
studied in E-MTAB-62

6 meta groups
studied in E-MTAB-62

Molecular subtype
studied in E-GEOD-21653

organ
studied in E-GEOD-24283

Organism
studied in E-TABM-84

Organism status
studied in E-GEOD-19188

Performer
studied in E-GEOD-2004, E-LGCL-5

Phenotype
studied in E-GEOD-22152, E-GEOD-21750, E-GEOD-1657, E-GEOD-1460, E-GEOD-17636, ... (6 experiments)

Population
studied in E-MTAB-197, E-GEOD-4922, E-GEOD-4342

Progesterone receptor status
studied in E-GEOD-3494, E-GEOD-6532, E-GEOD-20194, E-GEOD-16716

Protocol type
studied in E-GEOD-3254, E-GEOD-19445, E-GEOD-19246, E-GEOD-1343

Replicate
studied in E-GEOD-10896

RNAi
studied in E-GEOD-12438, E-MEXP-1509, E-GEOD-1676, E-MEXP-101, E-GEOD-3697, ... (7 experiments)

Sample preparation
studied in E-GEOD-16728

sampleID
studied in E-GEOD-24283

Sampling time point
studied in E-GEOD-19743, E-GEOD-17400, E-GEOD-18995

sbr grade
studied in E-GEOD-21653

Sex
studied in E-GEOD-2466, E-GEOD-7307

Stimulation
studied in E-GEOD-20114, E-GEOD-11886, E-GEOD-11428

stimulus
studied in E-GEOD-22103

Strain or line
studied in E-MEXP-1996, E-TABM-125

Subtype
studied in E-GEOD-24283

Survival time
studied in E-GEOD-3494, E-GEOD-19188

Test result
studied in E-GEOD-1926, E-TABM-276

Treatment
studied in E-GEOD-16837, E-MEXP-973, E-GEOD-21909, E-GEOD-19246, E-GEOD-19815, ... (6 experiments)

Treatment code
studied in E-GEOD-20194, E-GEOD-16716

Treatments comments
studied in E-GEOD-20194, E-GEOD-16716

Tumor grading
studied in E-GEOD-4290, E-GEOD-1561

Tumor size
studied in E-GEOD-4922

Vehicle
studied in E-GEOD-5258

Processing time: 0.398 secs.
 
Gene Expression Atlas 2.0.11.1- 12/23/11 3:09:34 PM